Aileron Therapeutics Inc.'s wider series E round of $48 million came as a result of upped attention from investors, thanks to "work that's gone on during the last 10 months," said Joseph Yanchik, CEO of the Cambridge, Mass.-based firm, which is developing stapled-peptide technology.
Specifically, the cash will push toward the clinic ALRN-6924, a specific re-activator of tumor suppressor protein p53 that targets the MDM2 and the MDMX suppressor proteins. Aileron disclosed its plan for a $30 million financing last November. P53, encoded by the TP53 gene, has long been dubbed the "guardian of the genome" because of its role in preventing mutations. (See BioWorld Today, Nov. 19, 2013.)
"As [Aileron] got